{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:43:52Z","timestamp":1774302232775,"version":"3.50.1"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Currently, only a few options are available for the treatment of patients with small\u2010cell lung cancer (SCLC) after the failure of first\u2010line platinum\u2010based chemotherapy. The present study aimed to evaluate the efficacy and safety of apatinib plus chemotherapy for second\u2010line treatment of advanced SCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>This prospective clinical trial recruited patients treated with apatinib plus second\u2010line chemotherapy until disease progression or intolerable toxicity. Logrank test power analysis was used for calculating samples. The primary endpoint was progression\u2010free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 29\/31 enrolled patients were available for response evaluation until October 2019. The ORR and DCR were 27.59% (8\/29) and 96.55% (28\/29), respectively. The median PFS and OS were 7.36\u2009months and 14.16\u2009months, respectively, indicating better efficacy compared with the standard second\u2010line chemotherapies. The most common adverse events (AEs) were neutropenia (41.94%, 13\/31), followed by leucopenia (35.48%, 11\/31) and thrombocytopenia (25.81%, 8\/31). The grade 3\u20134 AEs occurred in 12 (38.71%) patients, of which neutropenia (19.35%, 6\/31), leucopenia (9.68%, 3\/31), and proteinuria (6.45%, 2\/31) were most common. Patients receiving an initial dose of apatinib 250\u2009mg had a better tolerance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Antiangiogenic therapy plus chemotherapy had encouraging efficacy in advanced SCLC patients, which provides an insight into the current status of second\u2010line therapy in SCLC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5217","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T07:15:29Z","timestamp":1662707729000},"page":"2979-2989","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase <scp>II<\/scp> study of antiangiogenic therapy (Apatinib) plus chemotherapy as second\u2010line treatment in advanced small cell lung cancer"],"prefix":"10.1002","volume":"12","author":[{"given":"Yinghui","family":"Xu","sequence":"first","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiru","family":"Gao","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-8396","authenticated-orcid":false,"given":"Hua","family":"He","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Qiu","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Ma","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Song","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2987-576X","authenticated-orcid":false,"given":"Kewei","family":"Ma","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.007"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1592116"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1061"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37263"},{"issue":"4","key":"e_1_2_11_6_1","first-page":"2367","article-title":"Survival in small cell lung cancer is independent of tumor expression of VEGF and COX\u20102","volume":"24","author":"Dowell JE","year":"2004","journal-title":"Anticancer Res"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(02)00112-4"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.3423"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4844"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp200"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1576-1"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.465"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00828-x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03823-4"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0583-6"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1226"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.024"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24853"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2092"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.261"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.7"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9930"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30035-X"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1717002"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0061-6"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.3105"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117106"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16926"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986706777585077"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0111"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S170678"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12624"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3998"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5392"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu094"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000588"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181898e32"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.10.21"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-529"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2764-8"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8585"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0640"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19908"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00735-1"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01290-z"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.071"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7682"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0519"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:26:50Z","timestamp":1732523210000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cam4.5217"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5217","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"2022-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}